{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:56:29Z","timestamp":1769270189835,"version":"3.49.0"},"reference-count":118,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deep\u2010vein thrombosis (DVT) can have a significant impact on a patient\u2019s life. In particular, the development of post\u2010thrombotic syndrome as a long\u2010term complication of DVT can have devastating consequences for the individual and impose a substantial economic burden on healthcare systems. Anticoagulants are the mainstay of DVT treatment; however, the current standard of care, a parenteral anticoagulant followed by a vitamin K antagonist, is associated with complex patient management, often resulting in suboptimal therapy. New, oral anticoagulants have been developed, and a direct thrombin inhibitor \u2010 dabigatran etexilate \u2010 and two direct Factor Xa inhibitors \u2010 rivaroxaban and apixaban \u2010 have completed and\/or have ongoing phase III trials in the treatment of venous thromboembolism. These agents do not have the drawbacks of the vitamin K antagonists and hold promise for more effective treatment of DVT, possibly resulting in a reduction in the incidence of post\u2010thrombotic syndrome.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2011.01733.x","type":"journal-article","created":{"date-parts":[[2011,11,12]],"date-time":"2011-11-12T00:25:41Z","timestamp":1321057541000},"page":"185-194","source":"Crossref","is-referenced-by-count":39,"title":["Healthcare burden associated with the post\u2010thrombotic syndrome and potential impact of the new oral anticoagulants"],"prefix":"10.1111","volume":"88","author":[{"given":"Paolo","family":"Prandoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032959"},{"key":"e_1_2_17_3_2","first-page":"291","article-title":"The postphlebitic syndrome; a study of possible factors in subjective disability","volume":"80","author":"Popkin RJ","year":"1954","journal-title":"Calif Med"},{"key":"e_1_2_17_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.17.2105"},{"issue":"3","key":"e_1_2_17_5_2","first-page":"1","article-title":"Long\u2010term consequences of deep vein thrombosis","volume":"28","author":"Leizorovicz A","year":"1998","journal-title":"Haemostasis"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358836X9800300112"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.17"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-009-0309-3"},{"key":"e_1_2_17_9_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5070\/D36XC40751","article-title":"The post\u2010thrombotic syndrome \u2013 a condition to prevent","volume":"14","author":"Pirard D","year":"2008","journal-title":"Dermatol Online J"},{"key":"e_1_2_17_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6819.107"},{"key":"e_1_2_17_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-009-0336-2"},{"key":"e_1_2_17_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6249.1167"},{"key":"e_1_2_17_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430100053006"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-198306000-00007"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.68.804.779"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(95)70050-1"},{"key":"e_1_2_17_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07601.x"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00004"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03294.x"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2004.09.027"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03339.x"},{"key":"e_1_2_17_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01824.x"},{"key":"e_1_2_17_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(02)00008-5"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1144"},{"key":"e_1_2_17_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03002.x"},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2011.06.021"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055289"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.2.327"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03180.x"},{"key":"e_1_2_17_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2010.09.018"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.03.016"},{"key":"e_1_2_17_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01648.x"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2001.115811"},{"key":"e_1_2_17_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2000.06419.x"},{"key":"e_1_2_17_36_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2001.118810"},{"key":"e_1_2_17_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01216.x"},{"key":"e_1_2_17_38_2","first-page":"599","article-title":"Factor V Leiden mutation in postthrombotic and non\u2010postthrombotic venous ulcers","volume":"137","author":"Hafner J","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_17_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-5574-9"},{"key":"e_1_2_17_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(95)70038-2"},{"key":"e_1_2_17_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.02.034"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-12-200212170-00008"},{"key":"e_1_2_17_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2004.10.025"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.01106.x"},{"key":"e_1_2_17_45_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH05-03-0146","article-title":"The post\u2010thrombotic syndrome: incidence and prognostic value of non\u2010invasive venous examinations in a six\u2010year follow\u2010up study","volume":"94","author":"Roumen\u2010Klappe EM","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_17_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-199174"},{"key":"e_1_2_17_47_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2002.122886"},{"key":"e_1_2_17_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2005.04.014"},{"key":"e_1_2_17_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0741-5214(93)90426-M"},{"key":"e_1_2_17_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(97)70188-5"},{"key":"e_1_2_17_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70303-9"},{"key":"e_1_2_17_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2005.08.007"},{"key":"e_1_2_17_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000031705.57473.1C"},{"key":"e_1_2_17_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2006.02.045"},{"key":"e_1_2_17_55_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38167.684444.3A"},{"key":"e_1_2_17_56_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-10-0640"},{"key":"e_1_2_17_57_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.546465"},{"key":"e_1_2_17_58_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060388"},{"key":"e_1_2_17_59_2","first-page":"s629","article-title":"Deep vein thrombosis: beyond the operating table","volume":"23","author":"Haas S","year":"2000","journal-title":"Orthopedics"},{"key":"e_1_2_17_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/230949900501300202"},{"key":"e_1_2_17_61_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2003.00204.x"},{"key":"e_1_2_17_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.12.005"},{"key":"e_1_2_17_63_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-6-199703150-00006"},{"key":"e_1_2_17_64_2","first-page":"1","article-title":"Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study","volume":"4","author":"Olin JW","year":"1999","journal-title":"Vasc Med"},{"key":"e_1_2_17_65_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1997.00063.x"},{"key":"e_1_2_17_66_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0658"},{"key":"e_1_2_17_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1095"},{"key":"e_1_2_17_68_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.5.1155"},{"key":"e_1_2_17_69_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01333.x"},{"key":"e_1_2_17_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.3.229"},{"key":"e_1_2_17_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0b013e3181d24562"},{"key":"e_1_2_17_72_2","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e32832e4954"},{"key":"e_1_2_17_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-007-0108-7"},{"key":"e_1_2_17_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-002-8415-9"},{"key":"e_1_2_17_75_2","first-page":"60","article-title":"The novel anticoagulants: entering a new era","volume":"139","author":"Bounameaux H","year":"2009","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_17_76_2","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00001"},{"key":"e_1_2_17_77_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181ae6dbe"},{"key":"e_1_2_17_78_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-05-0327"},{"key":"e_1_2_17_79_2","first-page":"1","article-title":"New oral anticoagulants in development: potential for improved safety profiles","volume":"7","author":"Bauer KA","year":"2010","journal-title":"Rev Neurol Dis"},{"key":"e_1_2_17_80_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161210793563338"},{"key":"e_1_2_17_81_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-241851"},{"key":"e_1_2_17_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.101"},{"key":"e_1_2_17_83_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-06-0361"},{"key":"e_1_2_17_84_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0659"},{"key":"e_1_2_17_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03091782"},{"key":"e_1_2_17_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-009-0409-0"},{"key":"e_1_2_17_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02552.x"},{"key":"e_1_2_17_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02899.x"},{"key":"e_1_2_17_89_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2010.tb03566.x"},{"key":"e_1_2_17_90_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"e_1_2_17_91_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003674397"},{"key":"e_1_2_17_92_2","unstructured":"SchulmanS EricssonH GoldhaberSZ KakkarAK KearonC KvammeM MismettiP SchellongS SchneeJ.Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism.XXIII Congress of The International Society on Thrombosis and Haemostasis Kyoto 23\u201328 July 2011. Abstract O\u2010TH\u2010033."},{"key":"e_1_2_17_93_2","volume-title":"XXIII Congress of The International Society on Thrombosis and Haemostasis","author":"Schulman S"},{"key":"e_1_2_17_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02473.x"},{"key":"e_1_2_17_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"key":"e_1_2_17_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3185"},{"key":"e_1_2_17_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_17_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0043-5"},{"key":"e_1_2_17_99_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025551"},{"key":"e_1_2_17_100_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.025569"},{"key":"e_1_2_17_101_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802361499"},{"key":"e_1_2_17_102_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.668020"},{"key":"e_1_2_17_103_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-160143"},{"key":"e_1_2_17_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_17_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.106"},{"key":"e_1_2_17_106_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-02-0097"},{"key":"e_1_2_17_107_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780802528625"},{"key":"e_1_2_17_108_2","unstructured":"Bayer Pharma AG.Summary of Product Characteristics.http:\/\/www.medicines.org.uk\/emc\/medicine\/21265\/ 2011."},{"key":"e_1_2_17_109_2","unstructured":"Boehringer Ingelheim International GmbH.Summary of Product Characteristics.http:\/\/www.medicines.org.uk\/emc\/medicine\/20760\/ 2011."},{"key":"e_1_2_17_110_2","unstructured":"Bristol\u2010Myers Squibb Pfizer EEIG.Summary of Product Characteristics.http:\/\/www.medicines.org.uk\/emc\/medicine\/24988\/ 2011."},{"key":"e_1_2_17_111_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"e_1_2_17_112_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04321.x"},{"key":"e_1_2_17_113_2","unstructured":"Therapeutic Goods Administration. Dabigatran (Pradaxa): risk of bleeding relating to usehttp:\/\/www.tga.gov.au\/safety\/alerts\u2010medicine\u2010dabigatran\u2010111005.htm.2011."},{"key":"e_1_2_17_114_2","unstructured":"Medscape.Deaths Prompt Safety Advisory in Japan.http:\/\/www.medscape.com\/viewarticle\/748143?src=rss 2011."},{"key":"e_1_2_17_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-009-0392-5"},{"key":"e_1_2_17_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(03)00917-0"},{"key":"e_1_2_17_117_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-1-199607010-00001"},{"key":"e_1_2_17_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.05.033"},{"key":"e_1_2_17_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.12.023"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01733.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2011.01733.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:42:27Z","timestamp":1741912947000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01733.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":118,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1600-0609.2011.01733.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01733.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]}}}